Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A
Department of Infectious Diseases, Klinikum der Johann Wofgang Goethe-Universitat, Medizinische Klinik, Germany.
AIDS. 1999 May 28;13(8):951-6. doi: 10.1097/00002030-199905280-00011.
HIV-induced CD4 lymphocyte depletion is partially reversed by antiretroviral therapy but it is unclear if the degree to which the CD4 count rises depends on viral suppression (if so, the extent of viral suppression required to achieve a maximal CD4 count rise), whether the rise is sustainable and whether it occurs in patients with CD4 count <10 x 10(6) cells/l. We aimed to address these issues.
We studied CD4 count and plasma HIV RNA values every 4 weeks for 72 weeks in 154 patients starting indinavir-containing regimens.
Mean baseline HIV RNA and CD4 count were 4.8 log10 copies/ml and 180 x 10(6) cells/l, respectively. Overall, there was a mean increase in CD4 count of 143 x 10(6) cells/l by 72 weeks. The adjusted mean increase (adjusted for initial viral load, CD4 count and age) was strongly related to the mean viral suppression over the follow-up period (P < 0.0001). Importantly, there was a highly significant difference (P = 0.0004) in the rise in CD4 count between those with 2-3 log suppression (161 x 10(6) cells/l) and those with > 3 log suppression (314 x 10(6) cells/l; mean 3.6 log suppression in this group), suggesting that with even greater suppression the rise in CD4 lymphocytes may be still larger. We also studied whether CD4 counts were still rising after 72 weeks in patients with sustained suppression of at least 3 log in viral load. There was a significant (P = 0.004; paired t-test) rise in count of 43 x 10(6) cells/l between weeks 64 and 72 in these patients, suggesting that regeneration continues at least up to 72 weeks after therapy, provided virus replication continues to be suppressed. Patients with initial CD4 counts < 10 x 10(6) cells/l experienced no smaller rises than those at higher levels, even after adjustment for other factors.
These results strongly support a direct causal relationship between HIV replication and CD4 lymphocyte count depletion. The rise in those with > 3 log suppression provides the best available indicator of the potential for natural CD4 regeneration in HIV-infected patients. However, since still greater CD4 count rises may be seen with more suppressive regimens, it may not be possible to study the intrinsic CD4 regenerative capacity until such regimens are available.
抗逆转录病毒疗法可部分逆转HIV诱导的CD4淋巴细胞耗竭,但尚不清楚CD4计数上升的程度是否取决于病毒抑制作用(如果是这样,实现最大CD4计数上升所需的病毒抑制程度),这种上升是否可持续,以及在CD4计数<10×10⁶个细胞/升的患者中是否会出现这种上升。我们旨在解决这些问题。
我们对154例开始含茚地那韦治疗方案的患者每4周研究一次CD4计数和血浆HIV RNA值,共研究72周。
平均基线HIV RNA和CD4计数分别为4.8 log₁₀拷贝/毫升和180×10⁶个细胞/升。总体而言,到72周时CD4计数平均增加了143×10⁶个细胞/升。调整后的平均增加量(根据初始病毒载量、CD4计数和年龄进行调整)与随访期间的平均病毒抑制作用密切相关(P<0.0001)。重要的是,病毒抑制2 - 3 log的患者(CD4计数增加161×10⁶个细胞/升)与病毒抑制>3 log的患者(CD4计数增加314×10⁶个细胞/升;该组平均病毒抑制3.6 log)之间的CD4计数上升存在高度显著差异(P = 0.0004),这表明抑制作用越强,CD4淋巴细胞的上升可能越大。我们还研究了病毒载量持续抑制至少3 log的患者在72周后CD4计数是否仍在上升。这些患者在第64周和第72周之间CD4计数显著上升(P = 0.004;配对t检验),增加了43×10⁶个细胞/升,这表明只要病毒复制持续受到抑制,治疗后至少到72周时CD4细胞再生仍在继续。初始CD4计数<10×10⁶个细胞/升的患者,即使在对其他因素进行调整后,其CD4计数上升幅度也不小于较高水平患者。
这些结果有力地支持了HIV复制与CD4淋巴细胞计数耗竭之间存在直接因果关系。病毒抑制>3 log的患者中CD4计数的上升为HIV感染患者自然CD4再生潜力提供了最佳可用指标。然而,由于更有效的抑制方案可能会使CD4计数有更大幅度的上升,在有这样的方案之前,可能无法研究CD4的内在再生能力。